GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding GH Research PLC changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 33 | 1 | 35 | +3 |
| Shares | 32.1M | 46.4K | 32.6M | +498.6K (+1.6%) |
| Value | $587.1M | $849.0K | $325.0M | −$261.3M (−44.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held GH Research PLC at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| PEAK6 Investments LLC | 23,317 | $276.7K | 0.01% |
| Private Advisor Group, LLC | 10,236 | $102.0K | 0.00% |
| Royal Bank of Canada | 5,466 | $55.0K | 0.00% |
| Tortoise Investment Management, LLC | 4,081 | $41.0K | 0.01% |
| Tower Research Capital LLC (TRC) | 897 | $8.00K | 0.00% |
Sold out (2)
Institutions that held GH Research PLC at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 150,000 | $2.74M |
| UBS Group AG | 100 | $2.00K |
Not filed for Q2 2022 yet (1)
Institutions that held GH Research PLC at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 46,417 | $849.0K |